checkAd

     166  0 Kommentare Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses - Seite 3

    ###

    Media Contacts:

    Europe:
                Thomas Pederson
                Carrotize PR & Communications
                +45 6062 9390
                tsp@carrotize.com

    U.S.
                Mike Beyer
                Sam Brown Inc.
                +1 312-961-2502
                mikebeyer@sambrown.com

    Certified Adviser:
    Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

    This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 14 December 2020.


    Lesen Sie auch

    Attachment


    Seite 3 von 3



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses - Seite 3 Press Release       Hørsholm, Denmark (14 December 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has amended its license agreement with Eisai Co., Ltd. (Tokyo, Japan) to expand Allarity’s field-of-use to …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer